A Pilot, Exploratory, Randomized, Phase 2 Safety Study Evaluating Tumor Cell (Plasma Cell) Mobilization and Apheresis Product Contamination in Plerixafor Plus Non-pegylated G-CSF Mobilized Patients and in Non-pegylated G-CSF Alone Mobilized Patients
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2017
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Multiple myeloma; Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 06 Oct 2016 Status changed from active, no longer recruiting to completed.
- 13 Jul 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.